依托泊苷联合铂类化疗对非小细胞肺癌患者肿瘤标志物的影响研究  

Effect of Etoposide Combined with Platinum-Based Chemotherapy on Tumor Markers in Patients with Non-Small Cell Lung Cancer

作　　者：邱家烷 林玉宗[1] 孙争强[1] 梁德川 苏淼毅 龚伟[1] QIU Jiawan;LIN Yuzong;SUN Zhengqiang;LIANG Dechuan;SU Miaoyi;GONG Wei(Tumor Radiotherapy Department,Quanzhou Guangqian Hospital,Quanzhou,Fujian,362321,China)

机构地区：[1]福建省泉州市光前医院肿瘤放射治疗科,福建泉州362321

出　　处：《中外医疗》2024年第27期90-93,共4页China & Foreign Medical Treatment

摘　　要：目的探讨依托泊苷联合铂类化疗对非小细胞肺癌(non-small cell lung cancer,NSCLC)患者肿瘤标志物的影响。方法随机选取2022年1月—2023年12月福建省泉州市光前医院肿瘤放射治疗科接受化疗的100例NSCLC患者为研究对象,根据不同化疗方法将其分为A组(50例)和B组(50例),分别给予依托泊苷联合顺铂化疗、依托泊苷联合洛铂化疗,评价两组患者临床疗效、肿瘤标志物水平及不良反应。结果两组的治疗总有效率比较,差异无统计学意义(P>0.05)。治疗后,两组的血清胃泌素释放肽前体、神经元特异性烯醇化酶、Ki-67蛋白及血管内皮细胞生长因子水平均下降,差异有统计学意义(P均<0.05),但两组比较,差异无统计学意义(P均>0.05)。A组的不良反应发生率为10.00%(5/50),低于B组的30.00%(15/50),差异有统计学意义(χ^(2)=6.250,P<0.05)。结论NSCLC患者接受依托泊苷联合顺铂或洛铂化疗,疗效相当,均能下调肿瘤标志物水平,但依托泊苷联合洛铂化疗的不良反应发生率较低。Objective To investigate the effect of etoposide combined with platinum-based chemotherapy on tumor markers in patients with non-small cell lung cancer(NSCLC).Methods From January 2022 to December 2023,100 patients with NSCLC who received chemotherapy in the Tumor Radiotherapy Department,Quanzhou Guangqian Hospital,Fujian Province were randomly selected as the research objects.According to different chemotherapy methods,they were divided into A group(50 cases)and B group(50 cases).Etoposide combined with cisplatin chemotherapy and etoposide combined with lobaplatin chemotherapy were given respectively.The clinical efficacy,tumor marker levels and adverse reactions were evaluated between two groups.Results There was no significant difference in the total effective rate between the two groups(P>0.05).After treatment,the levels of serum pro-gastrin-releasing peptide,neuron-specific enolase,Ki-67 protein and vascular endothelial growth factor in the two groups decreased,and the differences were statistically significant(all P<0.05),but there was no statistically significant difference between the two groups(all P>0.05).The incidence of adverse reactions in the B group was 10.00%(5/50),which was lower than 30.00%(15/50)in the A group,and the difference was statistically significant(χ^(2)=6.250,P<0.05).Conclusion NSCLC patients receiving etoposide combined with cisplatin or lobaplatin chemotherapy have comparable efficacy and can down-regulate the level of tumor markers,but the incidence of adverse reactions of etoposide combined with lobaplatin chemotherapy is low.

关 键 词：依托泊苷 铂类化疗 非小细胞肺癌 肿瘤标志物 

分 类 号：R5[医药卫生—内科学]